Pfizer, on third try, wins FDA nod for biosimilar of blockbuster Epogen/Procrit
admin 15th May 2018 Uncategorised 0After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of anemia drug Epogen/Procrit, a drug whose U.S. sales generated about $1.8 billion dollars last year for partners Amgen and Johnson & Johnson.
More: Pfizer, on third try, wins FDA nod for biosimilar of blockbuster Epogen/Procrit
Source: fierce